Spago Nanomedical AB’s Post

Innovative DLL3 Targeting Mechanisms Will Lead to New Approaches in SCLC, LCNEC: Promising abstracts surrounding DLL3 targeting for patients with lung and neuroendocrine cancer were presented at WCLC 2024. #finance #pharmacy #lifesciences

In this article, Dr Cristian Massacesi, AstraZeneca discusses his ambitions for IO, the solutions he’s utilizing to realize them, and where we still need to put our focus to make real gains in cancer treatment. https://lnkd.in/eEdh7GTu #clinicalresearch #cancerimmunotherapy #immunooncology #cancerresearch #IO360nyc #immunotherapy Cristian Massacesi, M.D.

A thoughtful review on development of ADCs, H&N cancer focused, but with implications on general ADC development https://lnkd.in/erNuzHZG

Interesting study in Clinical Cancer Research: A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer https://lnkd.in/eHJr-3Y9 Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Patients with mCRPC refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy received target acapatamab doses ranging from 0.003 mg–0.9 mg in dose exploration (7 dose levels) and 0.3 mg (recommended phase 2 dose) in dose expansion intravenously Q2W. Safety (primary objective), pharmacokinetics, and antitumor activity (secondary objectives) were assessed. Results: In all, 133 patients (dose exploration, n=77; dose expansion, n=56) received acapatamab. Cytokine release syndrome (CRS) was the most common treatment-emergent adverse event seen in 97.4% and 98.2% of patients in dose exploration and dose expansion respectively; grade ≥ 3 was seen in 23.4% and 16.1%, respectively. Most CRS events were seen in treatment cycle 1; incidence and severity decreased at/beyond cycle 2. In dose expansion, confirmed prostate-specific antigen responses (PSA50) were seen in 30.4% of patients and radiographic partial responses in 7.4% (RECIST 1.1). Median PSA progression-free survival (PFS) was 3.3 months (95% CI, 3.0–4.9), radiographic PFS per PCWG3 was 3.7 months (95% CI, 2.0–5.4). Acapatamab induced T-cell activation and increased cytokine production several-fold within 24h of initiation. Treatment-emergent antidrug antibodies were detected in 55% and impacted serum exposures in 36% of patients in dose expansion. Conclusions: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.

Theralase Technologies (TSXV: TLT) has added over US$8B to its addressable market after demonstrating that its lead drug, Rutherrin, can destroy non-small cell lung cancer in a pre-clinical setting. #cancer #cancerresearch #cancerdrugs #stocks #stockstowatch #stocksinfocus #microcapstocks

Advances With Various Therapies Targeting DLL3 in Lung Neuroendocrine Tumors: An overview of the latest developments in targeting DLL3 in lung neuroendocrine tumors were presented at the 2024 World Conference on Lung Cancer. #finance #pharmacy #lifesciences

Results of a meta-analysis support the use of ketoconazole for patients with previously treated castration-resistant prostate cancer who experience a persistent rise in prostate specific-antigen (PSA) levels. https://brnw.ch/21wKSaB

🌟 Revolutionizing Breast Cancer Treatment! 🌟 AI-powered virtual clinical trials are transforming how we test new drugs, making the process faster, cheaper, and safer. Discover how this innovative approach is accelerating life-saving treatments in our latest blog! Link: https://lnkd.in/ghszge68 #BreastCancerAwareness #AIinHealthcare #VirtualClinicalTrials #blog #bie #biedx